After a delay, the Alpha-3 study faces an April futility analysis.
ApexOnco Front Page
Recent articles
A first-in-human trial of PRT12396 starts next month.
Talapro-3 could help move Talzenna into earlier prostate cancer.
The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April.
The company reveals its anti-GPRC5D T-cell engager.
The company’s TRPV1 antagonist looks doomed.
First human data on MK-2010 are imminent.
The company admits defeat with zelenectide.
